Skip to main content

Table 1 Published or ongoing trials of immunotherapy in EC:

From: Immunotherapy in endometrial cancer: rationale, practice and perspectives

Mechanism of action

NCI identifie

Agents

Phase

Setting/cancer type

Patient number

Subtype contribution

Outcomes

Status

anti-PD-1

antibody

NCT01876511

Pembrolizumab

II

Advanced MMR-deficient Cancers including EC

Total:86, EC:15

all MMR-d

ORR, DCR, PR, SD, PD

published

NCT02054806

Pembrolizumab

Ib

PD-L1 positive Advanced EC

24

POLE:1, MSI-high:1, MSS:17, Not evaluable:5

ORR, median PFS, median OS, PR, SD, PD

published

NCT02628067

Pembrolizumab

II

Noncolorectal MMR-d cancers including EC

Total:233, EC:49

all MMR-d

CR, PR, ORR, median PFS, median OS, median DOR

published

NCT02465060

Nivolumab

II

Noncolorectal MMR-d cancers including EC

Total:42, EC:13

all MMR-d

ORR, CR, PR, SD, PD, median PFS

published

Abti-PD-1 antibody+

Antiangiogenic therapy

NCT03015129

Pembrolizumab+

Lenvatinib

II

rEC

108

MSI:11,MSS:94

ORR, PFS, OS, DOR

published

anti-PD-L1 antibody

NCT01375842

Atezolizumab

Ia

rEC

15

MSI-H:1, MSS:7, unknown for MMR status:7

ORR, PFS,OS

published

NCT02912572

Avelumab

II

rEC

33

MSS:16, MSI:17

OR, PFS6

published

ACTRN12617000106336

Durvalumab

II

advanced EC

71

MSI:36, MSS:35

OTR, PFS, OS

published

anti-PD-L1 antibody+

anti-CTLA-4

NCT03015129

Durvalumab and Tremelimumab versus Durvalumab Monotherapy

II

rEC and Endometrial Carcinosarcoma

Total:56, EC:41

MSI:5, MSS:48, unknown:3

ORR, median DOR, PFS, PFS rate at 24 wks

published

tumor antigen loaded DC cancer vaccine

EudraCT 2009-016868-37

WT1mRNA-electroporated mature DCs (DCm-WT1-

RNA)

I/II

Uterine Tumor

Total:6, serous EC:3

NA

PFS, OS, Oncologic outcome

(CT Scan,

CA125),

Immune Response

(WT1-specific T-cells, NK cells)

published

peptide cancer vaccine+

anti-tumor cytokine

NCT01580696

E39 peptide waccine+

GM-CSF

I/IIa

Ovarian and EC

Total:51, EC:9

NA

DFS

published

Chimeric peptide cancer vaccine

BB-IND-9803

B-cell epitopes of HER2-Th (MVF) epitope chimeric peptide vaccine

I

Metastatic and/or Recurrent Solid Tumors including EC

Total:24, EC:1

NA

antibody response, PR, SD

published

nucleic acid-based cancer vaccine+

anti-PD-1 antibody

NCT03313778

mRNA-4157 vaccine+

Pembrolizumab

I

Resectable/Unresectable Solid Tumors including EC

Total:33, EC:1

MSI

PR, SD, PD, neoantigen-specific T cell response

published

ACT+

hyperthermia+

anti-PD-1 antibody/

chemotherapy

NCT03757858

Autologous Adoptive T cell Transfer+

Hyperthermia+

Pembrolizumab/

Chemotherapy

I

Advanced Solid Tumors including EC

Total:33, EC:5

NA

ORR, DCR, Clinical Response

(CR, PR, SD, PD)

published

anti-PD-1 antibody

NCT02628067

Pembrolizumab

II

Advanced Solid Tumors including EC

NA

NA

ORR

Recruiting

NCT02630823

Pembrolizumab

I

Surgically Resectable EC

NA

NA

AEs

Active, not recruiting

NCT02728830

Pembrolizumab

I

Gynecologic Cancers including EC

NA

NA

Fold change in tumor Immune Infiltrates

Active, not recruiting

NCT02899793

Pembrolizumab

II

Advanced, Recurrent or Metastatic EC

NA

POLE,MSI

ORR,AEs

Recruiting

NCT03241745

Nivolumab

II

Metastatic or Recurrent Uterine Cancer

NA

all dMMR(EC)

PFS

Recruiting

NCT03568539

IBI308

Ib

Advanced or Metastatic Solid Tumors including EC

NA

NA

Overall Response Rate,CR,PR

Active, not recruiting

anti-PD-1 antibody+

Surgery

NCT03694834

Pembrolizumab+

Hysterectomy+

Surgical staging

I

Early Stage, High Grade Obesity-driven EC

NA

NA

TIL

Suspended

anti-PD-1 antibody+

Surgery+

Chemotherapy

NCT03932409

Pembrolizumab+

Vaginal Cuff Brachytherapy+

Paclitaxel+

Carboplatin

Ib

High Intermediate Risk EC

NA

NA

Proportion of patients completing three cycles

Not yet recruiting

anti-PD-1 antibody+

Chemotherapy

NCT02549209

Pembrolizumab+\Carboplatin+

Paclitaxel

II

Advanced, Recurrent

or Metastatic EC

NA

NA

ORR

Recruiting

NCT03276013

Pembrolizumab+

Doxorubicin

II

Advanced, Recurrent

or Metastatic EC

NA

NA

PFS

Active, not recruiting

NCT03981796

Dostarlimab+

Carboplatin-

Paclitaxel

III

Advanced, Recurrent

or Metastatic EC

NA

will

do MMR evaluation

PFS

Recruiting

NCT03914612

Pembrolizumab+

Paclitaxel+

Carboplatin

III

Stage III/IV

or Recurrent EC

NA

will

do MMR evaluation

PFS

Recruiting

anti-PD-1 antibody+Radiotherapy

NCT04214067

Pembrolizumab+

Radiation therapy

III

High Intermediate Risk Endometrioid EC

NA

all dMMR

3 year recurrence

-free survival

Not yet recruiting

NCT03955978

Dostarlimab+

Standard of Care Definitive Radiation

I

Inoperable EC

NA

NA

Safety and tolerability

Recruiting

anti-PD-1 antibody+PARP inhibitor

NCT03016338

Dostarlimab+

Niraparib

II

Advanced,Recurrent or Metastatic EC

NA

NA

Clinical benefit rate

Recruiting

NCT03572478

Nivolumab+

Rucaparib

Ib/IIa

Advanced or Recurrent EC and Metastatic Castrate-Resistant Prostate Cancer

NA

NA

DLT rate

Recruiting

anti-PD-1 antibody+

Antiangiogenic therapy

NCT04197219

Pembrolizumab+

Axitinib

II

Advanced, Recurrent or Metastatic EC

NA

all dMMR

ORR,CR,

PR

Not yet recruiting

NCT02501096

Pembrolizumab+

Lenvatinib

Ib/II

metastatic Solid Tumors including EC

NA

NA

MTD,ORR,DLT

Active, not recruiting

NCT03367741

Nivolumab+

Cabozantinib

II

Advanced, Recurrent or Metastatic EC

NA

NA

PFS

Suspended

NCT03517449

Pembrolizumab+

Lenvatinib

III

Advanced, Recurrent or Metastatic EC

NA

will do MMR evaluation

PFS,OS

Active, not recruiting

NCT03884101

Pembrolizumab+

Lenvatinib

III

Advanced, Recurrent or Metastatic EC

NA

will do MMR evaluation

PFS,OS

Recruiting

NCT04157491

anti-PD-1 antibody+

Anlotinib

II

Advanced, Recurrent or Metastatic EC

NA

NA

ORR,CR,

PR

Recruiting

anti-PD-1 antibody+IDO inhibitor

NCT02178722

Pembrolizumab+

Epacadostat (INCB024360)

I/II

Cancers including EC

NA

NA

TEAEs, ORR

Active, not recruiting

NCT04106414

Nivolumab+

BMS-986205

II

Recurrent or Persistent EC or Endometrial Carcinosarcoma

NA

will do MMR evaluation

Best overall response rate

Recruiting

anti-PD-1 antibody+

anti-CTLA-4 antibody

NCT02982486

Nivolumab+

Ipilimumab

II

Nonresectable or Metastatic EC and Sarcoma

NA

all dMMR

CR,PR

Not yet recruiting

anti-PD-1 antibody+

4-1BB antibody

NCT03917381

GEN1046

I/II

Malignant Solid Tumors including EC

NA

NA

DLT,AEs,

Safety laboratory parameters

Recruiting

anti-PD-1 antibody+

CFTR inhibitor

NCT04014530

Pembrolizumab+

Ataluren

I/II

Metastatic EC and Colorectal Adenocarcinoma

NA

all dMMR(EC)

ORR

Recruiting

anti-PD-1 antibody+

Dual Adenosine Receptor

(A2aR/A2bR) Antagonist

NCT03629756

Zimberelimab (AB122)+

AB928

I

Advanced Solid Tumors including EC

NA

NA

DLTs,AEs

Recruiting

anti-PD-1 antibody+

FRα ADC

NCT03835819

Pembrolizumab+

Mirvetuximab Soravtansine (IMGN853)

II

Advanced, Recurrent or Metastatic EC

NA

all MSS

ORR, PFS

Recruiting

anti-PD-1 antibody+

Hormone

NCT04046185

Toripalimab+

Progesterone

I

Early EC

(preserve fertility)

NA

NA

Pathologic complete

/patrial remission rate

Not yet recruiting

anti-PD-1 antibody+IAP

NCT04122625

Nivolumab+

Mimetic

Debio 1143

Ib/II

Solid Tumors including EC, progressed during/immediately after anti-PD-1/PD-L1 treatment

NA

known MMR status

ORR

Recruiting

anti-PD-1 antibody+

Immune Modulatory Cocktail+

Radiotherapy+

Food supplement

NCT03192059

Pembrolizumab+

Immune Modulatory Cocktail

(Vitamin D+

Lansoprazole Teva+

Cyclophosphamide+Aspirine,)

+Radiotherapy

+Curcumin

II

Refractory or Recurrent EC, CC, Uterine sarcoma

NA

NA

ORR

Recruiting

anti-PD-1 antibody+

multi-targeted RTK inhibitor

NCT03827837

Camrelizumab+

Famitinib

II

Advanced RCC/UC/CC/EC and Recurrent OC

NA

NA

Overall response rate

Recruiting

anti-PD-1 antibody+

PVRIG antibody

NCT03667716

COM701 monotherapy or COM701+

Nivolumab

Ia/b

Advanced or Metastatic Solid Tumors including EC

NA

NA

AEs ,DLTs,MTD, RDFE

Recruiting

anti-PD-L1 antibody

NCT02725489

Durvalumab+Vigil

II

Advanced Women's Cancers including EC

NA

NA

AEs

Active, not recruiting

NCT03212404

Cosibelimab

I

Advanced

or Metastatic Solid Tumors including EC

NA

NA

DLT,AEs,ORR

Recruiting

anti-PD-L1 antibody+

Chemotherapy

NCT02914470

Atezolizumab+

Carbplatin+

Cyclophophamide

Ib

Advanced Gynaecologic Cancer including EC,BC

NA

NA

Toxicity, Incidence of toxicity,AEs

Active, not recruiting

NCT03503786

Avelumab+

Carboplatin+

Paclitaxel

II

Advanced, Recurrent

or Metastatic EC

NA

NA

PFS

Not yet recruiting

NCT03603184

Atezolizumab+

Paclitaxel+

Carboplatin

III

Advanced, Recurrent

or Metastatic EC

NA

Will do MMR evaluation

OS,PFS

Recruiting

anti-PD-L1 antibody+

Antiangiogenic therapy

NCT03170960

Atezolizumab+

Cabozantinib

Ib

Advanced or Metastatic Solid Tumors including EC

NA

NA

MTD/RD,ORR

Recruiting

NCT03526432

Atezolizumab+ Bevacizumab

II

Advanced, Recurrent or Metastatic EC

NA

will do MMR evaluation

Number of patients who experience CR or PR

Recruiting

anti-PD-L1 antibody+PARP inhibitor

NCT02912572

Avelumab/

Avelumab+

Talazoparib

II

Advanced, Recurrent or Metastatic EC

NA

POLE,MSI,MSS

PFS

Recruiting

NCT03101280

Atezolizumab+

Rucaparib

Ib

Advanced Gynecologic Cancers inclunding EC, TNBC

NA

NA

AEs,DLTs,RP2D,Number of Dose Modifications due to AEs

Active, not recruiting

NCT03951415

Durvalumab+

Olaparib

II

Advanced, Recurrent or Metastatic EC

NA

NA

PFS

Recruiting

anti-PD-L1 antibody+

Chemotherapy+

PARP inhibitor

NCT04269200

Durvalumab+

Carboplatin+

Paclitaxel+

Olaparib

III

Advanced, Recurrent or Metastatic EC

NA

will do MMR evaluation

PFS

Not yet recruiting

anti-PD-L1 antibody+

Antiangiogenic therapy+

PARP inhibitor

NCT03694262

Atezolizumab+

Bevacizumab+

Rucaparib

II

Advanced, Recurrent or Metastatic EC

NA

will do MMR evaluation

Overall Response Rate

Recruiting

anti-PD-L1 antibody+

IDO inhibitor

NCT02471846

Atezolizumab+

GDC-0919

Ib

Advanced or Metastatic Solid Tumors including EC

NA

NA

DLTs,AEs

Completed

anti-PD-L1 antibody+

anti-CTLA-4 antibody

NCT03015129

Durvalumab+

Tremelimumab

II

Persistent or Recurrent EC and Endometrial Carcinosarcoma

NA

NA

Overall Response Rate

Recruiting

anti-PD-L1 antibody+

anti-CTLA-4 antibody+

Radiotherapy

NCT03277482

Durvalumab+

Tremelimumab+

Radiotherapy

I

Recurrent Gynecologic Cancer including EC

NA

NA

MTD

Recruiting

anti-PD-L1 antibody+

anti-5T4 antibody-superantigen fusion protein

NCT03983954

Durvalumab+

Naptumomab

Ib/II

Advanced or Metastatic Solid Tumors including EC

NA

NA

AEs,MTD,RP2D

Recruiting

Dual Blockade

of PD-1 and CTLA-4

NCT03517488

XmAb20717

I

Advanced Solid Tumors including EC

NA

all dMMR(EC)

AEs

Recruiting

anti-B7-H4 antibody

NCT03514121

FPA150

Ia/b

Advanced or Metastatic Solid Tumors including EC

NA

NA

MTD,RD,AEs

Active, not recruiting

anti-LAG-3 antibody

NCT03538028

INCAGN02385

I

Advanced or Metastatic Solid Tumors including EC

NA

all dMMR(EC)

TEAEs

Recruiting

  1. CR Complete Response, DCR Disease Control Rate, DOR Duration of Response, OR Objective Response, ORR Objective Response Rate, OS Overall Survival, OTR Objective Tumour Response, PD Progressive Disease, PFS Progression-Free Survival, PFS6 Progression-Free Survival at 6 months, PR Partial Response, rEC advanced or recurrent EC, SD Stable Disease, ADC Antibody-drug conjugates, AEs Adverse Events, BC Breast Cancer, CC Cervical Cancer, DLTs Dose-Limiting Toxicities, MTD Maximum Tolerated Dose, OC Ovarian Cancer, RCC Renal Cell Carcinoma, RD Recommended Dose, RDFE Recommended Dose for Expansion, RP2D Recommended Phase II Dose, TEAEs Treatment-Emergent Adverse Events, TIL Tumor Infiltrating Lymphocytes, TNBC Triple-Negative Breast Cancer, UC Urothelial Carcinoma.